First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2014-04-04 11:29:53Open Document File Size: 621,34 KBShare Result on FacebookCountryCanada / /CurrencyUSD / /FacilityCanadian Institute / /IndustryTermchemical level / antipsychotic products / treatment of mania or bipolar disorder / sound pharmaceutical policies / treatment of schizophrenia and related psychotic disorders / treatment of behavioural and psychological symptoms / chemical / chemicals / antipsychotic product / /MedicalConditionrelated dementias / Alzheimer’s disease / schizophrenia / dementia / mania / bipolar disorders / psychotic disorders / disorders / bipolar disorder / /NaturalFeatureEdward Island / /OrganizationRoyal Canadian Mounted Police / World Health Organization / Correctional Service of Canada / Demography Division / Canadian Institute for Health Information / United States Food and Drug Administration / /Positionphysician / /Productolanzapine / clozapine / Interest Antipsychotic / donepezil / risperidone / rivastigmine / /ProvinceOrStateAlberta / New Brunswick / Saskatchewan / Manitoba / Prince Edward Island / Nova Scotia / Ontario / /RadioStationNova / /URLwww.cihi.ca/drugs / /SocialTag |